Login to Your Account



Money in hand, Alcobra focuses ‘attention’ on ADHD

By Marie Powers
Staff Writer

Thursday, February 6, 2014
Alcobra Ltd. didn’t set out to address attention deficit hyperactivity disorder (ADHD), an indication with a number of approved drugs – including Ritalin (methylphenidate, Novartis AG), Concerta (a different formulation of methylphenidate, Johnson & Johnson) and Adderall XR (d-amphetamine, Shire plc) – as well as spectacular failures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription